TearScience develops integrated in-office systems to identify and treat evaporative dry eye and is headquartered in Morrisville, North Carolina. Its product suite includes the LipiView Ocular Surface Interferometer, which measures the lipid layer thickness of the tear film, and the LipiFlow Thermal Pulsation System, which unblocks Meibomian glands during an in-office procedure. In its first year after product launch TearScience sold more than 100 systems and treated thousands of dry eye sufferers, demonstrating early commercial traction. The company targets the worldwide dry eye market (more than 100 million sufferers globally and roughly 23 million in the U.S.), noting that about 86% of cases are evaporative dry eye. TearScience aims to fully execute global commercialization efforts and establish its system as the standard of care for evaporative dry eye by addressing the root cause—Meibomian Gland Dysfunction—and restoring natural lipid production for a healthy tear film. TearScience is a medical device company that develops devices used by eye care professionals to diagnose and treat the most common form of chronic dry eye disease. The company has achieved CE Mark certification to market its devices in Europe and is currently seeking U.S. FDA clearance. Products are expected to be commercially available within the next 12 months. TearScience completed a $44.5M Series C financing to support commercialization. The funding will allow the company to commercialize its devices. The company is based in Morrisville, North Carolina.

Total raised

$115M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2013